CompoAtlas

Bifidobacterium animalis subsp. lactis LAFTI B94

Natural health product licensed in Canada

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Bifidobacterium animalis subsp. lactis

Source : Cellule entière

5 Milliards d'UFCNot calculated

Non-medicinal ingredients

Maltodextrine, Saccharose, Extrait de Levure, Acide ascorbique

PopulationAgeQuantity per servingFrequency
Sous-population S/Ominimum: 6 years1 packet1 Tous les jours
AdultesNot specified1 packet2 Tous les jours
Sous-population S/Ominimum: 4 years1 packet2 Tous les jours
Enfantsmaximum: 6 years1 packet1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Ages 0 months (birth) and older: Source of probiotics. Ages 0 months (birth) and older: Helps support intestinal/gastrointestinal health. Ages 0 months (birth) and older: Could promote a favorable gut flora. Aged 0 months (birth) and older: Participates in a healthy microflora balance. Ages 4 and above: helps to relieve abdominal discomfort, such as bloating and constipation. Ages 4 and above: Helps children and adolescents with bloating and constipation in irritable bowel syndrome (IBS). Adults: In adjunct with anti-helicobacter pylori therapy, helps to improve the Helicobacter pylori eradication rate. Adults: An adjunct to physician-supervised therapy in patients with Helicobacter pylori infections. Adults: Helps to reduce adverse effects from Helicobacter pylori therapy such as loss of appetite, diarrhea, nausea, headache, dizziness, and abdominal pain.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Other names
Bifidobacterium animalis subsp. lactis (R0421)
Licence holder
Lallemand Health Solutions (Institut Rosell)
NPN or DIN-HM
80077056
Status
Active licence
Licence date
28 April 2017
Revision date
22 September 2021
Form
Poudre
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80077056

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Photograph the packaging

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Bifidobacterium animalis subsp. lactis LAFTI B94”, https://compoatlas.com/en/supplements/canada/80077056-bifidobacterium-animalis-subsp-lactis-lafti-b94, updated 22 September 2021.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line